Autolus Therapeutics plc (AUTL) NASDAQ
1.75
-0.09(-4.89%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Autolus Therapeutics plc
Address
The MediaWorks
London, W12 7FP
United Kingdom of Great Britain and Northern Ireland (the)
Phone
44 20 3829 6230
Website
Sector
Healthcare
Industry
Biotechnology
Employees
647
First IPO Date
June 22, 2018
Key Executives
| Name | Title | Pay | Year Born |
| Christian Martin Itin | Chief Executive Officer & Director | 2.69M | 1964 |
| Chris Williams | Senior VP & Chief Business Development Officer | 0 | 1980 |
| Martin Pule MBBS | Founder, Senior Vice President & Chief Scientific Officer | 0 | 1972 |
| Matthias Will | Senior Vice President & Chief Development Officer | 0 | 1973 |
| Alexander Swan | Senior Vice President & Chief Human Resources Officer | 0 | 1965 |
| Alex Driggs | Senior Vice President of Legal Affairs & General Counsel and Secretary | 0 | 1976 |
| Christopher Vann | Senior Vice President & Chief Operating Officer | 0 | 1965 |
| Patrick McIlvenny | Senior VP of Finance, Chief Accounting Officer & Principal Accounting Officer | 0 | 1980 |
| Robert F. Dolski | Senior Vice President & Chief Financial Officer | 0 | 1971 |
| Olivia Manser | Director of Investor Relations | 0 | N/A |
| Amanda Cray | Executive Director of Investor Relations & External Communications | 0 | N/A |
| Dilip Patel | Senior Vice President of Leading Global Pricing & Market Access Srategy | 0 | N/A |
| Miranda Neville | Senior VP & Chief Technology Officer | 0 | 1975 |
| Vesna Cizej | Senior Vice President of Strategic Development | 0 | N/A |
Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
